KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Twist Bioscience (TWST) Equity Average (2018 - 2026)

Twist Bioscience has reported Equity Average over the past 9 years, most recently at $455.6 million for Q1 2026.

  • Quarterly Equity Average rose 1.69% to $455.6 million in Q1 2026 from the year-ago period, while the trailing twelve-month figure was $455.6 million through Mar 2026, up 1.69% year-over-year, with the annual reading at $472.8 million for FY2025, 13.73% down from the prior year.
  • Equity Average was $455.6 million for Q1 2026 at Twist Bioscience, down from $464.5 million in the prior quarter.
  • Over five years, Equity Average peaked at $842.0 million in Q2 2022 and troughed at $448.0 million in Q1 2025.
  • The 5-year median for Equity Average is $575.1 million (2024), against an average of $597.8 million.
  • Year-over-year, Equity Average surged 37.51% in 2022 and then dropped 24.76% in 2024.
  • A 5-year view of Equity Average shows it stood at $767.9 million in 2022, then fell by 20.98% to $606.7 million in 2023, then dropped by 23.47% to $464.3 million in 2024, then rose by 0.05% to $464.5 million in 2025, then decreased by 1.92% to $455.6 million in 2026.
  • Per Business Quant, the three most recent readings for TWST's Equity Average are $455.6 million (Q1 2026), $464.5 million (Q4 2025), and $475.6 million (Q3 2025).